Drugs & TargetsFree Keytruda receives two sBLA acceptances from FDA in TNBC in indications July 31, 2020Vol.46 No.31
Drugs & TargetsFree HIF-2α inhibitor MK-6482 receives FDA Breakthrough Designation for Von Hippel-Lindau Disease-associated RCC July 31, 2020Vol.46 No.31
Drugs & TargetsFree Engineered macrophage immunotherapy receives IND clearance from FDA July 31, 2020Vol.46 No.31
Drugs & TargetsFree BDTX-189 receives FDA Fast Track Designation for solid tumors harboring HER2 or EGFR mutations July 31, 2020Vol.46 No.31
Drugs & TargetsFree Tagrisso receives FDA Breakthrough Therapy Designation for adjuvant treatment of stage IB-IIIA EGFR-mutated lung cancer July 31, 2020Vol.46 No.31
Drugs & TargetsFree Piqray receives approval in Europe for HR+/HER2- advanced breast cancer with a PIK3CA mutation July 31, 2020Vol.46 No.31
Drugs & Targets FDA accepts Karyopharm’s sNDA for Xpovio as a treatment for multiple myeloma after at least one prior line of therapy July 24, 2020Vol.46 No.30
Drugs & Targets FDA issues draft guidance to encourage cannabis-related clinical research July 24, 2020Vol.46 No.30
Drugs & Targets FDA proposes rule on reporting requirement under Right to Try Act July 24, 2020Vol.46 No.30
